Emactuzumab, a humanized monoclonal antibody targeting CSF1/CSF1R, inhibit tumor cell proliferation and metastasis by blocking the activity of CSF1R‐dependent TAMs, suppressing the recruitment of TAMs to the microenvironment, and enhancing the T‐cell infiltration.367. Here, CSF1R is linked to neoplasm.